IP Library Granted Patent US 10,463,722
Granted Patent B2
US 10,463,722 · App. 15/673,937 · Granted Nov 5, 2019

Vaccine compositions against pathogenic fungi and methods for use thereof

Inventors: Maurizio Del Poeta (Mount Sinai, NY); Antonella Rella (Port Jefferson Station, NY)
Assignee: The Research Foundation for The State University of New York
A61K39/0002A61P31/10C12N9/2402C12P19/44C12P19/56C12P33/00C12Y302/01A61K2039/52A61K2039/522
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,463,722
App. No.
15/673,937
Granted
Nov 5, 2019
Kind
B2
Abstract

The present disclosure provides compositions comprising mutant fungi include an inactive form of the sterylglucosidase enzyme. The present disclosure is also directed to vaccine based compositions, which include a mutant fungus that prohibit pathogenic fungal infection. This disclosure also provides methods for administering these compositions as a prophylaxis against fungal infection, as well as methods for isolating sterylglucosides that include the use of such mutant fungal compositions.

Claims (14)

1. A composition comprising a mutant fungus, wherein the endogenous Sterylglucosidase (Sgl1) gene is inactivated.

2. The composition of claim 1 , wherein said mutant fungus lacks the ability to metabolize sterylglucosides (SGs).

3. The composition of claim 1 , wherein said mutant fungus accumulates sterol glycosides.

4. The composition of claim 1 , wherein said mutant fungus is avirulent.

5. The composition of claim 1 , wherein said mutant fungus is from a Cryptococcus genus.

6. The composition of claim 1 , wherein said mutant fungus is selected from the group consisting of Cryptococcus neoformans, Cryptococcus gatii, Cryptococcus albidus, Cryptococcus uniguttulatus, Candida albicans, Aspergillus fumigatus and other fungi in which the Sgl1 gene is deleted.

7. A method for producing sterylglucosides comprising:

providing a mutant fungus wherein the endogenous Sterylglucosidase (Sgl1) gene is inactivated;

growing the fungus, wherein the mutant fungus produces sterylglucosides; and

isolating said sterylglucosides.

8. The method of claim 7 , wherein said mutant fungus lacks the ability to metabolize sterylglucosides (SGs).

9. The method of claim 7 , wherein said mutant fungus accumulates sterol glycosides.

10. The method of claim 7 , wherein said mutant fungus is from a Cryptococcus genus.

11. The method of claim 7 , wherein said mutant fungus is selected from the group consisting of Cryptococcus neoformans, Cryptococcus gatii, Cryptococcus albidus, Cryptococcus uniguttulatus, Candida albicans, Aspergillus fumigatus and other fungi in which the Sgl1 gene is deleted.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2019
From: DEL POETA, MAURIZIO; RELLA, ANTONELLA
To: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Reel/Frame 050215/0191 →
CONFIRMATORY LICENSE Recorded Aug 17, 2017
From: STATE UNIVERSITY NEW YORK STONY BROOK
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 043580/0395 →
Continuity (2)
Provisional Application 62372894 · Aug 10, 2016
Related Publication 20180085442A1 · Mar 29, 2018